

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Jantzen, Hans-Michael, et al		
Divisional of Application No.:	09/947,922	Group No.:	N/A
Filed:	Herewith	Examiner:	N/A
For:	NOVEL PURINERGIC RECEPTOR		

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT

The information disclosure statement submitted herewith is being filed:

☒ Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

☐ *After* three months of the filing date of this national application or the date of entry of the national stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

☐ with sufficient postage as first class mail.

☒ as "Express Mail Post Office to Addressee"
Mailing Label No.: EV312194681USJ

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker/Carolyn Willey

Date: November 12, 2003

(type or print name of person certifying)

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI95-017P1RCN3DV1M

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

OR

☐ The information disclosure statement transmitted herewith is being filed *after* a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

☐ In accordance with the requirements of 37 C.F.R. Section 1.97(d):

A. ☐ Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

B. ☐ Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

C. ☐ No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

Practitioner's Docket No. MPI95-017P1RCN3DV1M


FEE PAYMENT

3. ☐ The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

☒ Applicant believes no fee is due in connection with this submission.

		Fee due	\$0.00
METHOD OF PAYMENT OF FEE			
4. <input type="checkbox"/> Attached is a check in the amount of \$ _____.			
<input checked="" type="checkbox"/> Charge Account No. 501668 in the amount of		\$0.00	.
<input type="checkbox"/> A duplicate of this request is attached.			

If any additional fees are due, please charge Account 501668.

<u>November 12, 2003</u>	MILLENNIUM PHARMACEUTICALS, INC. By  Jean M. Silveri Registration No. 39,030 75 Sidney Street Cambridge, MA 02139 Telephone - 617-679-7336 Facsimile - 617-551-8820
--------------------------	---

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Jantzen, Hans-Michael, et al
Divisional of Group No.: N/A
Application No.: 09/947,922
Filed: Herewith Examiner: N/A
For: NOVEL PURINERGIC RECEPTOR

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. ☒ Preliminary Statements
2. ☒ Copy of Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) as filed in parent application No. 09/947,922 filed September 7, 2001
3. ☒ Identification of Prior Application in Which Listed Information Was Already Cited and for Which No Copies Are Submitted or Need Be Submitted

Preliminary statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Patent Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

☐ with sufficient postage as first class mail.

☒ as "Express Mail Post Office to Addressee"
Mailing Label No.: EV312194681USJ

TRANSMISSION

☐ transmitted by facsimile to the Patent and Trademark Office.

Signature

Sean Hunziker/Carolyn Willey

Date: November 12, 2003

(type or print name of person certifying)

**WARNING: Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.*

Practitioner's Docket No. MPI95-017P1RCN3DV1M

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

**Identification of Prior Application in Which Listed Information Was Already Cited and for Which
No Copies Are Submitted or Need Be Submitted**


This application relies, under 35 U.S.C. section 120, on the earlier filing date of prior Application No. 09/947,922 filed on September 1, 2001.

(complete the following, if applicable)

- [x] This application also relies, under 35 U.S.C. section 120, on the earlier filing date of prior application SN.: 09/410,738 filed on October 1, 1999; application SN.: 08/749,707 (Patent No. 6,063,582) filed on November 15, 1996; and 08/599,524 (Patent No. 5,871,963), filed on November 15, 1995.

The references were submitted to, and/or cited by, the Office in the prior application(s) and, therefore, are not required to be provided in this application.

November 12, 2003

MILLENNIUM PHARMACEUTICALS, INC.
By 
Jean M. Silveri
Registration No. 39,030
75 Sidney Street
Cambridge, MA 02139
Telephone - 617-679-7336
Facsimile - 617-551-8820

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) (SUBSTITUTE) PTO Form 1449				Attorney Docket No. 044481-5010-03-US		Serial No. 09/947,922	
				Applicants Pamela B. CONLEY <i>et al.</i>			
				Filing Date September 7, 2001		Art Unit 1647	
U.S. PATENT DOCUMENTS							
*Examiner Initial		Document Number	Date	Name	Class	Sub Class	Filing Date
		5,441,883	8/15/95	Civelli <i>et al.</i>			
		5,596,088	1/21/97	Boucher <i>et al.</i>			
FOREIGN PATENT DOCUMENTS							
		Document Number	Date	Country	Class	Sub Class	<u>Translation</u> YES NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
		Chang <i>et al.</i> , "Molecular cloning and functional analysis of a novel P2 nucleotide receptor," <i>J Biol Chem</i> 270:26152-26158, 1995.					
		Conley <i>et al.</i> , "Cloning of a Novel Purinoreceptor from a Human Megacaryocytic Cell Line," <i>Blood</i> , p. 361a (Abstract 1433), 1995.					
		Harden <i>et al.</i> , "P ₂ purinergic receptors: sub-type associated signaling responses and structure," <i>Am Rev Pharmacol Toxicol</i> 35:541-579, 1995.					
		Henderson <i>et al.</i> , "Cloning and characterization of a bovine P _{2Y} receptor," <i>Biochemical and Biophysical Research Comm</i> 212(2):648-656, 1995.					
		Kim <i>et al.</i> , "Characterization of the Purinergic P. Receptors in PC12 Cells," <i>Journal of Biological Chemistry</i> 269(9):6471-6477, 1994.					
		Lustig, <i>et al.</i> , "Expression cloning of an ATP receptor from mouse neuroblastoma cells," <i>Proc Natl Acad Sci USA</i> 90:5113-5117, 1993.					
		Mohammed <i>et al.</i> , "Identification of two calcium-signaling P2U purinergic receptors in human erythro leukemia cells," <i>Experimental Biology</i> , Part 1, p. A117 (Abstract 684), 1995.					
		Parr <i>et al.</i> , "Cloning and expression of a human P2U nucleotide receptor, a target for cystic fibrosis pharmacotherapy," <i>Proc Natl Acad Sci USA</i> 91:3275-3279, 1994.					
		Rice, <i>et al.</i> , "Cloning and Expression of the Alveolar Type II Cell P _{2u} Purinergic Receptor," <i>Am J Respir Cell Mol Biol</i> 12:27-32, 1995.					
		Tokuyama, Y., <i>et al.</i> , "Cloning of Rat and Mouse P2y Purinoreceptor," <i>Biochemical and Biophysical Research Communications</i> 211(1):211-218, 1995.					
		Webb, <i>et al.</i> , "Cloning and functional expression of a brain G-protein-coupled ATP receptor," <i>FEBS</i> 324(2):219-225, 1993.					
		International Search Report in PCT Application No. PCT/US96/18175, May 20, 1997.					
Examiner				Date Considered			
Examiner:				Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			